Compare DAR & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAR | HALO |
|---|---|---|
| Founded | 1882 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.1B |
| IPO Year | 2002 | 2001 |
| Metric | DAR | HALO |
|---|---|---|
| Price | $63.21 | $77.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $65.82 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 2.4M | 1.8M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.83 | ★ 1.22 |
| Revenue | ★ $6,135,877,000.00 | $151,862,000.00 |
| Revenue This Year | $7.78 | $28.24 |
| Revenue Next Year | $3.37 | $12.56 |
| P/E Ratio | $73.69 | ★ $63.51 |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $29.15 | $55.64 |
| 52 Week High | $66.02 | $82.26 |
| Indicator | DAR | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 59.64 |
| Support Level | $56.74 | $67.12 |
| Resistance Level | $63.95 | $82.24 |
| Average True Range (ATR) | 1.86 | 2.47 |
| MACD | 0.78 | -0.32 |
| Stochastic Oscillator | 98.90 | 48.74 |
Darling Ingredients Inc develops and produces sustainable natural ingredients from edible and inedible bio-nutrients for the pharmaceutical, food, pet food, animal feed, industrial, fuel, bioenergy, and fertilizer industries. The Company collects and processes animal by-products and recycled oils into ingredients. It operates through three reportable segments: Feed Ingredients, which generates maximum revenue and includes the collection and processing of animal by-products, used cooking oil, bakery residuals, pet food ingredients, hides, and fertilizers; Food Ingredients, which includes collagen, natural casings, and food-grade fats; and Fuel Ingredients, which includes renewable fuels, biogas, and energy products. The Company derives the majority of its revenue from North America.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.